2020 - Successfully Navigating Cost Barriers to Deliver Low Cost Connectivity to the Pharmaceutical Industry

Connected medical devices, which allow tracking of medication and communication between patient and physician, is an important and emerging technology to minimize the costs of unmanaged health conditions. Connected devices may also be leveraged to monitor key biometrics in high-risk patient populations for injections diseases, including COVID-19. While patient acceptance of connected devices is improving, high costs associated with converting a traditional medical device to a connected medical device have remained a barrier to adoption of this technology.
In delivering low-cost connectivity to the pharmaceutical industry, it will be possible to (i) help patients and payers save significantly through better management of chronic health conditions, (ii) allow pharmaceutical companies to ensure patients take all medication as prescribed and (iii) assist physicians in improving patient healthcare outcomes and quality of life.